Supernus PharmaceuticalsSUPN
SUPN
About: Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Employees: 674
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
323% more call options, than puts
Call options by funds: $994K | Put options by funds: $235K
110% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 20
16% more capital invested
Capital invested by funds: $1.86B [Q3] → $2.15B (+$293M) [Q4]
7% more funds holding
Funds holding: 270 [Q3] → 290 (+20) [Q4]
9% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 94
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
0.64% less ownership
Funds ownership: 108.34% [Q3] → 107.71% (-0.64%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$36
17%
upside
Avg. target
$36
17%
upside
High target
$36
17%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Cantor Fitzgerald Kristen Kluska 24% 1-year accuracy 24 / 102 met price target | 17%upside $36 | Neutral Reiterated | 26 Feb 2025 |
Financial journalist opinion
Based on 22 articles about SUPN published over the past 30 days
Neutral
Accesswire
1 day ago
Supernus Pharmaceuticals, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Supernus Pharmaceuticals, Inc. (SUPN)
NEW YORK, NY / ACCESS Newswire / April 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
2 days ago
Supernus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - SUPN
NEW YORK, NY / ACCESS Newswire / April 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
3 days ago
Levi & Korsinsky Announces an Investigation on Behalf of Supernus Pharmaceuticals, Inc. (SUPN) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESS Newswire / April 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
4 days ago
SUPN STOCK ALERT: Levi & Korsinsky Notifies Supernus Pharmaceuticals, Inc. Investors of an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / April 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
5 days ago
Levi & Korsinsky Reminds Shareholders of an Investigation into Supernus Pharmaceuticals, Inc. (SUPN) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
1 week ago
Shareholders that lost money on Supernus Pharmaceuticals, Inc.(SUPN) should contact Levi & Korsinsky about Securities Fraud Investigation - SUPN
NEW YORK, NY / ACCESS Newswire / April 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
1 week ago
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Supernus Pharmaceuticals, Inc. (SUPN)
NEW YORK, NY / ACCESS Newswire / April 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
1 week ago
Levi & Korsinsky Announces an Investigation on Behalf of Supernus Pharmaceuticals, Inc. (SUPN) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
1 week ago
Supernus Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - SUPN
NEW YORK, NY / ACCESS Newswire / April 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Neutral
Accesswire
1 week ago
ATTENTION Supernus Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
Charts implemented using Lightweight Charts™